Our goal is simple:
Fix Genes, Bring Hope
Limelight Bio is pioneering new therapies that break down barriers of current genetic medicine to bring hope to as many patients and families as possible. Since 2017, Limelight has been developing proprietary technologies, advanced targets, and leading drug candidates designed to overcome key limitations of current gene therapy and gene editing approaches. Limelight is a privately held, multi-platform, multi-disease biopharmaceutical company headquartered in Philadelphia, PA and Cambridge, MA.